In analyzing the use of targeted therapies for metastatic EGFR- and ALK-altered NSCLC, we found substantial underprescribing of osimertinib and alectinib, with wide variation across state Medicaid programs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.